# Oncolytic Adenovirus Combined With PD-1 Inhibitor in Patients With Non-muscle-invasive Bladder Cancer

> **NCT05564897** · PHASE2 · UNKNOWN · sponsor: **Zhejiang Cancer Hospital** · enrollment: 25 (estimated)

## Conditions studied

- Bladder Cancer

## Interventions

- **DRUG:** H101, Camrelizumab

## Key facts

- **NCT ID:** NCT05564897
- **Lead sponsor:** Zhejiang Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-08-26
- **Primary completion:** 2024-09-30
- **Final completion:** 2024-12-31
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2022-10-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05564897

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05564897, "Oncolytic Adenovirus Combined With PD-1 Inhibitor in Patients With Non-muscle-invasive Bladder Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05564897. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*